Why the study?
Does resveratrol prevent cardiac hypertrophy and diastolic impairment in a rat model of pressure overload?
Does resveratrol prevent cardiac hypertrophy and diastolic impairment in a rat model of pressure overload?
In a rat model of pressure overload, resveratrol prevented concentric hypertrophy and diastolic impairment, highlighting its potential therapeutic value for hypertension and aortic valve stenosis.
Answers are grounded in this paper and cite their sources.
Should not yet change practice in hypertension or aortic stenosis; extends preclinical evidence for resveratrol in pressure overload.
This study was designed to examine the effects of the antioxidant resveratrol on cardiac structure and function in pressure overload (PO)-induced cardiac hypertrophy. Male Sprague-Dawley rats were subjected to sham operation and the aortic banding procedure. A subgroup of sham control and aortic-banded rats were treated with resveratrol for 2 wk after surgery. Echocardiographic analysis of cardiac structure and function along with Western blot analysis of endothelial nitric oxide synthase (eNOS), inducible nitric oxide synthase (iNOS), and redox factor-1 (ref-1) were performed in all groups after 4 wk of surgery. Banded rats showed significantly increased left ventricle-to-body weight ratio. Echocardiographic analysis showed that the interventricular septal wall thickness and left ventricular posterior wall thickness at systole and diastole were significantly increased in banded rats. Also, a significant increase in isovolumic relaxation time was observed in banded rats. Measured eNOS, iNOS, and ref-1 protein levels were significantly reduced in banded rats. Resveratrol treatment prevented the above changes in cardiac structure, function, and protein expression in banded rats. Aortic banding after 4 wk resulted in concentric remodeling and impaired contractile function due to PO on the heart. The 2-wk treatment with resveratrol was found to abolish PO-induced cardiac hypertrophy. Resveratrol may therefore be beneficial against PO-induced cardiac hypertrophy found in clinical settings of hypertension and aortic valve stenosis.
No takes yet. Share an insight, caveat, or question.
Juric et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: